APLLTD Share Price Performance
₹842.65
-184.45 (-17.96%)
7.1% undervalued intrinsic discount
₹907.20
Fair Value
Price ₹842.65
AnalystConsensusTarget ₹907.20
AnalystLowTarget ₹715.00
AnalystHighTarget ₹1,132.00
Fair Value₹907.20
Share Pricen/a
Alembic Pharmaceuticals Limited Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 7 Fair Values set on narratives written by author
APLLTD Community Narratives
AN
Fair Value
·Fair Value ₹907.2 7.1% undervalued intrinsic discount
US Product Launches And India Execution Will Expand Reach
0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AN
Fair Value
·Fair Value ₹715 17.9% overvalued intrinsic discount
Regulatory Scrutiny And Supply Issues Will Squeeze Pharma Prospects
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value
·Fair Value ₹1.13k 25.6% undervalued intrinsic discount
Aging Populations And Emerging Markets Will Transform Pharmaceutical Opportunities
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
US Product Launches And India Execution Will Expand Reach
Alembic Pharmaceuticals is betting that better execution in India and a steady stream of new US launches can restart growth and lift profitability. But intense price competition, rising development costs, and trade-policy uncertainty could keep results under pressure longer than expected.Read more
AN
₹907.2
7.1% undervalued intrinsic discount
Fair Value
Revenue
10.64% p.a.
Profit Margin
11.63%
Future PE
21.89x
Price in 2029
₹1.29k
Aging Populations And Emerging Markets Will Transform Pharmaceutical Opportunities
Alembic Pharmaceuticals is pushing hard into tougher-to-make medicines and new U.S. launches, and that mix shift could help it grow faster than many expect as demand rises in older and emerging-market populations. But heavy dependence on crowded export markets, regulatory surprises, and a weaker showing at home in India could all derail that momentum.Read more
AN
₹1.13k
25.6% undervalued intrinsic discount
Fair Value
Revenue
12.18% p.a.
Profit Margin
11.97%
Future PE
25.47x
Price in 2029
₹1.61k
Regulatory Scrutiny And Supply Issues Will Squeeze Pharma Prospects
Alembic Pharmaceuticals faces growing pressure from tougher rules, supply-chain shocks, and cutthroat competition in its biggest overseas market, which could slow new product rollouts and squeeze profits. At the same time, its push into harder-to-make medicines and efficiency upgrades could keep results improving—if it executes well and keeps pace with where the industry is headed.Read more
AN
₹715
17.9% overvalued intrinsic discount
Fair Value
Revenue
9.47% p.a.
Profit Margin
11.67%
Future PE
17.76x
Price in 2029
₹1.02k
Trending Discussion
No trending discussion available.
Recently Updated Narratives
AN
APLLTD: US Approvals And Exclusivity Opportunities Will Drive Upside
Fair Value: ₹907.2 7.1% undervalued intrinsic discount
3 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
APLLTD: USFDA Approvals For Key Therapies Will Drive Future Upside
Fair Value: ₹1.13k 25.6% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
APLLTD: US Generics Pipeline And Leadership Transition Will Shape Balanced Future Prospects
Fair Value: ₹715 17.9% overvalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Alembic Pharmaceuticals Limited Key Details
About APLLTD
- Founded
- 1907
- Employees
- 17244
- CEO
- WebsiteView website
Alembic Pharmaceuticals Limited, an integrated pharmaceutical company, develops, manufactures, markets, and sells pharmaceutical products in India and internationally. The company provides products in various therapeutic areas, such as cardiology, orthopaedics, anti-diabetic, ophthalmology, gynaecology, nephrology, gastrology, urology, dermatology, anti-infective, cold and cough, and animal health; generics formulations in oral solids, oncology oral solids and injectables, general injectables and ophthalmic products, dermatology, and oral suspension; and active pharmaceutical ingredients. It also exports its products. Alembic Pharmaceuticals Limited was founded in 1907 and is headquartered in Vadodara, India.
